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has protective eﬀects on many neurological diseases. Here,
we aimed to test G-CSF’s eﬀects on perihematomal tissue
injuries following intracerebral hemorrhage (ICH) and exam-
ine whether the eﬀects were functionally dependent on vas-
cular endothelial growth factor (VEGF) and aquaporin-4
(AQP4). We detected the expression of perihematomal
VEGF, VEGF receptors (VEGFRs) and AQP4 at 1, 3 and
7 days after ICH. Also, we examined the eﬀects of G-CSF
on tissue injuries by ICH in wild type mice, and tested
whether such eﬀects were VEGF and AQP4 dependent by
using VEGFR inhibitor – SU5416 and AQP4 knock-out
(AQP4/) mice. Furthermore, we assessed the related sig-
nal transduction pathways via astrocyte cultures. We found
G-CSF highly increased perihematomal VEGF, VEGFR-2 and
AQP4. Importantly, G-CSF led to neurological functional
improvement in both types of mice by associating with
reduction of brain edema, blood–brain barrier (BBB) perme-
ability and neuronal death and apoptosis and statistical
analysis suggested AQP4 was required for these eﬀects.
Besides, except BBB leakage alleviation, the above eﬀects
were attenuated but not counteracted by SU5416, suggest-
ing involvement of VEGF. G-CSF up-regulated phosphoryla-0306-4522  2013 The Authors. Published by Elsevier Ltd.
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Open access under CC BY-tion of extracellular signal-regulated kinase (ERK) and
signal transducer and activator of transcription 3 (STAT3)
as well as VEGF and AQP4 proteins in cultured astrocytes.
The latter was inhibited by ERK and STAT3 inhibitors
respectively. Our data suggest the protective eﬀects of
G-CSF on perihematomal tissue injuries after ICH are
highly associated with the increased levels of VEGF
and AQP4, possibly act through C-Jun amino-terminal
kinase and ERK pathways respectively.
 2013 The Authors. Published by Elsevier Ltd.
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INTRODUCTION
Granulocyte-colony stimulating factor (G-CSF) is a
hematopoietic growth factor which plays important roles
in proliferation and diﬀerentiation of myeloid cells. In
recent years, various experimental studies have shown
that G-CSF has protective eﬀects on many neurological
diseases, such as stroke, Parkinson’s disease,
amyotrophic lateral sclerosis, etc. (Meuer et al., 2006;
Popa-Wagner et al., 2010; Pollari et al., 2011). There is
suﬃcient evidence on its neuroprotective eﬀects on
cerebral ischemic models. Apart from promoting stem
cell mobilization and targeting to brain, apoptosis
reduction and inﬂammation inhibition in acute phase as
well as neurogenesis promotion and angiogenesis
enhancement in chronic phase were also indicated as
playing a role (Solaroglu et al., 2006; Zhao et al., 2006;
Sehara et al., 2007; Popa-Wagner et al., 2010;
Sugiyama et al., 2011). But as to intracerebral
hemorrhage (ICH), another type of stroke, few studies
have been conducted. The key hemorrhagic damages
are perihematomal tissue injuries, the main
manifestations of which are formation of brain edema,
disruption of blood–brain barrier (BBB), cell death and
apoptosis, etc. caused by substances from central
nervous system (CNS) cells disruption and red blood
cells lysis. It was found that G-CSF decreased
perihematomal brain edema, BBB permeability and
numbers of apoptotic cells (Park et al., 2005). However,
the eﬀects were only observed on isolated time points
without dynamic observation and the involved
mechanisms remain unknown.
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channel in CNS, mainly plays an important role in
formation and resolution of brain edema. Previous work
from our group indicated that AQP4 knock-out
aggravated brain edema, worsened neurological deﬁcits
and increased cell injuries after ICH, suggesting AQP4
had positive eﬀects on ICH (Tang et al., 2010). Vascular
endothelial growth factor (VEGF) is another important
factor that has protective eﬀects on many neurological
diseases by acting on neurons and glial cells. Our
previous research demonstrated that VEGF alleviated
perihematomal tissue injuries by reducing brain edema,
neuronal death and neurological deﬁcits (Chu et al.,
2013).
The main pathway activated by G-CSF to elicit
biological eﬀects is Janus kinase/signal transducer and
activator of transcription (JAK/STAT) pathway (Harada
et al., 2005). In addition, G-CSF can also activate
phosphatidylinositol 30-kinase (PI3K)/Akt and mitogen-
activated protein kinase (MAPK) pathways, including
extracellular signal-regulated kinase (ERK), C-Jun
amino-terminal kinase (JNK) and p38-MAPK pathways
(Carvalho et al., 2011). Interestingly, VEGF can also be
up-regulated via JAK/STAT3 pathway (Loeﬄer et al.,
2005). One study demonstrated G-CSF increased
VEGF and its receptor depending on JAK/STAT
pathway (Jung et al., 2006). Besides, the inhibitors of
MAPKs suppressed AQP4 up-regulation induced by
manganese-treatment or oxygen-glucose deprivation
and recovery (Rao et al., 2010; Qi et al., 2011). Based
on the above evidences that G-CSF is closely related
with VEGF and AQP4, both of which are essential to
perihematomal tissue injuries, we speculate that the
eﬀects of G-CSF on ICH may result from regulating
VEGF and AQP4 expression via certain pathways.
To test these hypotheses, we injected G-CSF
intraperitoneally after ICH and examined the changes of
perihematomal tissue injuries and expression of VEGF
and AQP4 in wild-type (AQP4+/+) mice. We also
investigated whether eﬀects of G-CSF were VEGF and
AQP4 dependent using VEGF receptor (VEGFR)
inhibitor and AQP4 knock-out (AQP4/) mice.
Furthermore, we examined which signal transduction
pathways could be activated by G-CSF to regulate
VEGF and AQP4 expression through astrocyte cultures.EXPERIMENTAL PROCEDURES
Animals and experimental groups
Male AQP4+/+ and AQP4/ mice, 3–4 month-old,
weighing 25–33 g, were kindly provided by Doctor Hu,
Jiangsu Key Laboratory of Neurodegeneration,
Department of Anatomy, Histology and Pharmacology of
Nanjing Medical University in China. Mice were kept in
the environment of a 12-h-light/dark cycle with free
access to food and water. Our animal studies and
protocols were approved by the Institutional Animal
Care and Use Committee of Fudan University.
AQP4+/+ mice were randomly divided into six groups:
Group 1: Control. Group 2: Control plus G-CSF. Group 3:
Sham operation. Group 4: ICH. Group 5: ICH plus G-CSF.Group 6: ICH plus G-CSF plus SU5416, a VEGFR-2
inhibitor. Groups of AQP4/ mice were the same as
AQP4+/+ mice except absence of Group 6. The
parameters were measured at 1, 3 and 7 days after
operation and each parameter of each group contained
six mice.Mouse ICH model and drugs injection
Mice were anesthetized with 10% chloralhydrate (350 mg/
kg) and were placed in a stereotaxic frame (Alcott
Biotech, Shanghai, China). Through a hole drilled in the
skull, a 32-gauge needle was implanted into the
striatum, 2.0 mm lateral to the midline, 1.0 mm anterior
to the coronal suture and at a depth of 4.0 mm from the
surface of the brain. Each mouse was microinjected
with 5 ll of autologous whole blood (right striatum)
taken from the tail vein over 10 min using a 5-ll
microinfusion pump (ALC-IP600, Alcott Biotech). Then
the needle was pulled out without blood reﬂux after
5 min dwelling and the wound was sutured. Only the
mouse with neurological deﬁcit was regarded as a
successful model. The mice in sham operation group
had the same operation but no blood was injected.
According to previous studies (Park et al., 2005) and
our preliminary experiment (four doses: 5, 15, 50 and
150 lg/kg), recombinant human G-CSF (rhG-CSF,
Millipore, Billerica, MA, USA) was injected
intraperitoneally with a dose of 50 lg/kg at 2 h after ICH
induction and daily afterward for 7 days. SU5416 (60 lg/
kg Sigma–Aldrich, St. Louis, MO, USA) was injected
intracerebroventricularly (0.9 mm lateral to the midline,
0.1 mm posterior to the coronal suture and at a depth of
3.1 mm from the surface of the brain) immediately after
ICH (Lee and Agoston, 2010). The same dose of
normal saline was injected intraperitoneally as control.Astrocyte culture and groups
Astrocyte culture was prepared as previously reported
(Yang et al., 2008). Cerebral cortices from neonatal
Sprague–Dawley rat brains were removed and carefully
dissected. The tissue was dissociated in Dulbecco’s
Modiﬁed Eagle Medium (DMEM) containing 0.0025%
trypsin/EDTA (Gibco, Carlsbad, CA, USA) and passed
through a 70-mm pore nylon mesh. After centrifugation,
the cell pellet was resuspended in DMEM/F12 medium
containing 10% fetal bovine serum (FBS), 50 U/ml
penicillin, and 50 mg/ml streptomycin (all from Gibco),
and then plated onto 25-ml tissue culture ﬂasks. The
medium was renewed every 2–3 days. After incubation
for 5–7 days, the cells were trypsinized and subcultured
in 60-mm diameter culture dishes. The cell population
consisted of over 95% astrocytes as determined by
immunocytochemical staining with anti-glial ﬁbrillary
acidic protein (GFAP) antibody (Millipore).
The astrocytes were randomly divided into seven
groups. Group 1: Normal astrocytes. Group 2: G-CSF
(100 ng/ml). Group 3: G-CSF plus U0126 (10 lmol/L,
Invivogen, San Diego, CA, USA), an ERK inhibitor.
Group 4: G-CSF plus SB239063 (10 lmol/L, Enzo Life
Sciences Inc., Farmingdale, NY, USA), a p38-MAPK
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Invivogen), a JNK inhibitor. Group 6: G-CSF plus
AG490 (0.1 lmol/L, Invivogen), a STAT3 inhibitor.
Group 7: G-CSF plus Ly294002 (30 lmol/L, Invivogen),
a PI3K inhibitor. The doses of drugs were according to
our preliminary experiment (four doses of rhG-CSF: 10,
50, 100 and 250 ng/ml) and previous reports (Habas
et al., 2006; Kawasaki et al., 2007; Sinke et al., 2008;
Kojima et al., 2011).Neurological testing
A standardized battery of behavioral tests was used to
quantify sensorimotor neurological function at 1, 3 and
7 days after ﬁrst injection. The battery consisted of two
tests: the postural reﬂex test, which examines upper-
body posture while the animal was suspended by the
tail, and the forelimb placing test, which examines
sensorimotor integration in forelimb placing responses
to visual, tactile, and proprioceptive stimuli. Neurological
function was graded on a scale of 0–12 (normal score
0, maximal score 12) as previously described (Belayev
et al., 2003). Tests were conducted by an observer
blinded to the treatment group.Brain water content
Brain was rapidly removed from the skull at 1, 3 and
7 days after operation and the olfactory bulbs and brain
stem with the cerebellum were eliminated before water
contents were measured, which were performed less
than 2 min after the decapitation. After the wet weight of
ipsilateral (hemorrhage) hemisphere was measured, the
tissue was then dried at 100 C for 24 h, and its dry
weight was measured. Brain water content (as a
percentage) = (wet weight  dry weight)/wet
weight  100% (Agrawal et al., 1968).Brain speciﬁc gravity
For determination of speciﬁc gravity, a linear kerosene/
brombenzene gradient was prepared. Appropriate
volumes of two stock solutions with a speciﬁc gravity of
SG= 0.9750 g/cm3 and SG= 1.0650 g/cm3 were
mixed with a gradient mixer (LKB Ultrograd 11300). The
outﬂow of the mixer was connected to a graded cylinder
containing a volume of 100 ml. During the ﬁlling process
the cylinder was lowered to maintain a steady ﬂow to
the surface of the gradient. The cylinder, the connecting
tubes, and the beakers containing the stock solutions
were kept at a constant temperature of 25 C in a
heated water bath. After 12 h the gradient was
calibrated with 5-ll droplets of potassium sulfate
solutions with speciﬁc calculated gravities of 1.0250,
1.0300, 1.0400 and 1.0450 g/cm3, respectively. After
removing, the brain was cut into a 2-mm slice with the
center as needle entry point. Six tissue samples
surrounding hematoma were removed from the slice
with Pasteur pipettes of 3-mm diameter. The samples
were immersed into the gradient, and the speciﬁc
gravity was read from the column exactly 90 s later
(Tang et al., 2010).Determination of BBB permeability with the use of
Evans Blue
Evans Blue (EB, Sigma–Aldrich) in normal saline (2%,
4 ml/kg) was injected intravenously at 1, 3 and 7 days
after operation. The mice were anesthetized 1 h later
and perfused with 200 ml of normal saline solution
through the left cardiac ventricle. They were decapitated
and the tissue samples surrounding hematoma were
obtained as mentioned above. The samples were
homogenized in methylformamide (1 ml/100 mg brain
tissue), incubated for 24 h at 60 C, and centrifuged for
5 min at 1000g. The absorbance (A) of supernatants
was analyzed at 632 nm by spectrophotometry. The
amount of EB (lg/g) was calculated through standard
curve established by known concentrations of EB.
ELISA for VEGF protein expression
VEGF protein levels were measured using mouse VEGF
enzyme-linked immunosorbent assay (ELISA) kit (R&D
Systems Inc., Minneapolis, MN, USA). Sample
homogenates and culture supernatants preparation and
assays were performed as recommended by the
manufacturer. The protein levels of VEGF in brain
tissues were normalized and expressed as pg per mg of
total protein.
Western blotting
Protein extraction: (1) In vivo experiment: Brain
hemispheres (hemorrhage) were homogenized in RIPA
lysis buﬀer (Beyotime, Suzhou, China) and 1 mmol/L
phenylmethanesulfonyl ﬂuoride (PMSF). (2) In vitro
experiment: The culture ﬂuid of each group of
astrocytes was discarded 48 h after drugs administration
and the cells were treated with RIPA lysis buﬀer and
PMSF. Additionally, astrocytes of Group 2 were treated
in the same way at 0, 12, 24, 48 and 72 h after drugs
administration. After centrifugation, the supernatant was
used for analysis. Proteins (50 lg) were loaded onto 4%
stacking/12% separating sodium dodecyl sulfate (SDS)–
polyacrylamide gels for electrophoresis, and then
transferred onto nitrocellulose transfer membranes. After
blocking, membranes were incubated overnight at 4 C
with anti-AQP4 (1:1000, Sigma–Aldrich), anti-p-JNK
(1:1000, CST, Boston, MA, USA), anti-p-ERK (1:1000,
CST), anti-p-p38 (1:1000, CST), anti-p-STAT3 (1:1000,
CST), and anti-p-Akt (1:1000, CST) rabbit polyclonal
antibodies. Membranes were then incubated for 1 h at
room temperature with horseradish peroxidase (HRP)
labeled goat anti-rabbit secondary antibody (1:4000,
Vector, Burlingame, CA, USA). The membranes were
placed into ECL solution for 5 min, and then exposed.
The intensity of blots was quantiﬁed using the Leica
Image Processing and Analysis System. b-Actin was
used as an internal control.
Immunoﬂuorescence
Specimen preparation: (1) In vivo experiment: AQP4+/+
mice were anesthetized at 1, 3 and 7 days after
operation and perfused with normal saline solution and
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ventricle. Brain tissues were removed and gradient
dehydrated. Serial coronal sections (10 lm) were then
cut on a freezing microtome (CM 1900, Leica, Wetzlar,
Germany). (2) In vitro experiment: The coverslips full of
astrocytes were taken out at 48 h after drugs
administration. Each group of astrocytes was ﬁxed by
4% paraformaldehyde for 30 min. After washing, the
sections were blocked by 10% goat serum. Sections
were incubated overnight at 4 C with anti-AQP4 rabbit
polyclonal antibody (1:500, Sigma–Aldrich), and then
incubated 1 h at 37 C with ﬂuorescein isothiocyanate
(FITC) coupled secondary goat anti-rabbit
immunoglobulin G (IgG) (1:500, Invitrogen). The
astrocytes were also stained with 40,6-diamidino-2-
phenylindole (DAPI) for highlighting the nuclei.
Terminal deoxynucleotidyl transferase-mediated
dUTP nick end labeling (TUNEL) staining
Mice were treated as in ‘‘immunoﬂuorescence’’ part to
obtain brain sections. After washing, the sections were
stained for TUNEL using In Situ Cell Death Detection Kit
(Roche, Mannheim, Germany), following the protocol
provided by the manufacturer. Sections were also
stained with DAPI for highlighting the nuclei.
Nissl staining
Brain frozen sections were obtained by method in
‘‘immunoﬂuorescence’’ part. Sections were stained with
Toluidine Blue (Sigma–Aldrich) for 20 min. After washing
by distilled water, sections were separated by color with
95% ethanol for 30 s.
Cell counting
For determining cell counts, coronal sections of 10 lm
were cut from the optic nerve to mamillary body. Every
other section was chosen after the needle entry site
was ﬁrst spotted. The brain sections through the needle
entry site starting with the ﬁrst appearance of TUNEL or
Nissl staining cells, extending to the most caudal parts
of the hematoma zone were TUNEL or Nissl staining at
1, 3 and 7 days after operation (n= 6 per group). Six
brain sections per mouse were selected according to
the principle that it provides most variability in TUNEL or
Nissl staining when compared to control group. Mean
number of positive cells per section was recorded.
Statistical analysis
All data were presented as mean ± standard error of
mean (SEM) and analyzed with SPSS12.0. Diﬀerences
between groups were compared by using a one-way
analysis of variance (ANOVA). When the ANOVA
identiﬁed signiﬁcant between-group diﬀerences, Tukey’s
honestly signiﬁcant diﬀerence (HSD) tests were used for
intergroup comparisons. Two-tailed Student t tests were
for comparisons between AQP4+/+ and AQP4/ mice
in each group. In addition, we added a two-way ANOVA
with replication in sections containing AQP4+/+ andAQP4/ mice to examine whether interactions existed
between G-CSF injection and presence of AQP4 gene.RESULTS
Eﬀects of diﬀerent doses of G-CSF in in vivo and
in vitro experiments
We used four doses of rhG-CSF from low to high to
determine the optimal one. We found rhG-CSF of 5 mg/
kg had no eﬀects and 15 mg/kg only reduced brain
edema at 1 day and alleviated neurological deﬁcits at
7 days after ICH as well as up-regulated AQP4 at each
time point and VEGF at 1 day (p< 0.05). Both doses of
50 and 150 mg/kg developed more protective eﬀects
and higher levels of AQP4 and VEGF proteins than
another two doses (p< 0.05). So we chose 50 mg/kg in
our subsequent experiments. In in vitro experiment, low
dose did not have any eﬀects. Another three doses of
rhG-CSF up-regulated VEGF and AQP4 expression and
levels of the two proteins were higher in doses of 100
and 250 ng/ml (p< 0.05). So we selected 100 ng/ml as
experimental dose (Fig. 1).Expression of AQP4 protein in each group of
AQP4+/+ mice
Immunoﬂuorescence showed the AQP4 staining was
vascular based on structure with green ﬂuorescence
and abundantly expressed in groups of control plus G-
CSF, ICH, ICH plus G-CSF and ICH plus G-CSF plus
SU5416 at each time point after operation. Meanwhile,
both Western blot and immunoﬂuorescence revealed an
increase of AQP4 protein at striatum after 1, 3 and
7 days by intraperitoneal rhG-CSF injection in normal
mice (p< 0.05). Furthermore, perihematomal
AQP4 protein expression was increased by rhG-CSF at
the three time points after ICH, which was not
changed by intracerebroventricular injection of
SU5416. The statistical diﬀerences were found in
semi-quantitative analysis of Western blot (p< 0.05)
(Figs. 2, 3A, B).Expression of VEGF and its receptors in each group
of AQP4+/+ mice
ELISA showed intraperitoneal rhG-CSF injection up-
regulated VEGF protein expression at striatum of
normal mice at all time points. Meanwhile,
perihematomal VEGF protein expression (pg per mg of
total protein) was increased by rhG-CSF at 1, 3 and
7 days (p< 0.05) after ICH, which was not inﬂuenced
by intracerebroventricular SU5416 injection (Fig. 3E).
VEGF has two main receptors: VEGFR-1, also called
fams-like tyrosine kinase-1 (Flt-1) and VEGFR-2, also
called fetal liver kinase-1 (Flk-1). There was no eﬀect of
rhG-CSF on Flt-1 expression whether at normal state or
after ICH. However, intraperitoneal injection of rhG-CSF
signiﬁcantly increased Flk-1 expression both at normal
state and after ICH at the three time points (p< 0.05)
(Fig. 3C, D).
Fig. 1. Results of our preliminary experiment. Intraperitoneal rhG-CSF injection of 5 mg/kg had no eﬀects while 15 mg/kg alleviated brain edema at
1 day and neurological deﬁcits at 7 days after ICH as well as up-regulated AQP4 at each time point and VEGF at 1 day (n= 6, ⁄p< 0.05 vs. ICH).
There were less brain water content, neurological scores and higher levels of AQP4 and VEGF proteins in groups of 50 and 150 mg/kg than another
two doses (n= 6, #p< 0.05 vs. groups of ICH, 5 and 15 mg/kg). In cultured astrocytes, rhG-CSF administration of 10 ng/ml did not make any
change and 50 ng/ml increased VEGF and AQP4 expression from 24 h (n= 6, ⁄p< 0.05 vs. 0 h). Higher levels of VEGF and AQP4 proteins were
found at 12 h after rhG-CSF administration and lasted within 72 h in groups of 100 and 250 ng/ml (n= 6, #p< 0.05 vs.0 h and groups of 10 and
50 ng/ml). (A) Brain water content. (B) Neurological scores. (C) Expression of AQP4 surrounding the hematoma. (D) Expression of VEGF
surrounding the hematoma. (E) Expression of AQP4 in cultured astrocytes. (F) Expression of VEGF cultured astrocytes.
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extravasation amount of AQP4+/+ and AQP4/ mice
Brain water content and brain speciﬁc gravity are two
methods for measuring perihematomal brain edema,
and the main advantage of the latter is the
possibility to obtain reliable results in small brain
tissues. Expectably, the results were consistent
with each other. Since we focused on perihematomal
brain edema, we chose brain tissues also
surrounding hematoma for investigating VEGF’s eﬀect
on BBB permeability. RhG-CSF had no eﬀect on
normal mice in these sections. Injection of rhG-CSF
intraperitoneally reduced brain edema and EB
extravasation surrounding hematoma in both types of
mice at 1, 3 and 7 days after ICH (p< 0.05), but
the injuries were more severe in AQP4/ mice than
AQP4+/+ mice in both ICH and ICH plus G-CSF
groups (p< 0.05) (Fig. 4A–C). Intracerebroventricular
injection of SU5416 weakened but not counteractedG-CSF’s eﬀect on brain edema, while eﬀect of
G-CSF on BBB permeability remained unchanged
(p< 0.05) (Fig. 5A–C). To investigate whether these
eﬀects of G-CSF had something to do with AQP4,
we studied the interactions between G-CSF injection
and presence of AQP4 gene by a two-way
ANOVA with replication. The F (p) values were 5.21
(0.033), 4.86 (0.039) and 6.77 (0.017) (brain
water content); 4.60 (0.044), 4.83 (0.039) and 5.29
(0.032) (brain speciﬁc gravity); 6.13 (0.022), 5.61
(0.040) and 6.33 (0.020) (EB), suggesting presence
of interactions.Neurological scores of AQP4+/+ and AQP4/ mice
There was no inﬂuence of rhG-CSF on normal mice in this
section. Meanwhile, more severe neurological deﬁcits
were found in AQP4/ mice than AQP4+/+ mice at 1,
3 and 7 days after ICH (p< 0.05). Injection of rhG-CSF
Fig. 2. Immunoﬂuorescence of AQP4 protein expression in each AQP4+/+ group. (A) Negative control without primary antibody gave negative
result with no detectable AQP4 labeling. (B) High magniﬁcation for group of ICH+ G-CSF 3 days after operation (red arrow of K) showed AQP4
labeling was concentrated in glial end-feet surrounding intracerebral capillaries. (C–F) Groups of control, control plus G-CSF 1, 3 and 7 days after
ﬁrst injection. (G–J) Groups of sham operation, ICH 1, 3 and 7 days. (K-M) Groups of ICH plus G-CSF 1, 3 and 7 days after ICH. (O–Q) Groups of
ICH plus G-CSF plus SU5416 1, 3 and 7 days after ICH. The AQP4 staining was vascular based on structure with green ﬂuorescence and
abundantly expressed after ICH and rhG-CSF injection at normal striatum as well as surrounding the hematoma at any chosen time point.
Intracerebroventricular injection of SU5416 did not change G-CSF’s above eﬀects. Asterisks represent the hematoma zones. Scale bar = (B)
50 lm, (A, C–Q) 100 lm.
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types of mice (p< 0.05), while the neurological
functions were still better in AQP4+/+ mice (p< 0.05)
(Fig. 4D). SU5416 attenuated but did not counteract the
protective eﬀect of G-CSF (Fig. 5D). A two-way
ANOVA with replication revealed the F values
were 5.21, 5.98 and 4.62 with the corresponding
p values of 0.033, 0.024 and 0.044, suggesting
presence of interactions.TUNEL and Nissl staining and cell counting of
AQP4+/+ and AQP4/ mice
TUNEL staining was to detect perihematomal apoptotic
cells and positive cells were double-labeled by TUNELand DAPI staining. Nissl staining was used for
evaluating neuronal death resulting from ICH and Nissl
staining positive cells were survival neurons. The
changing trend of TUNEL and Nissl staining cells was
shown in microscopic images (Figs. 6 and 7). We made
quantitative analysis by means of positive cell counting.
RhG-CSF had no inﬂuence on neural death or apoptosis
in both types of normal mice. There were more TUNEL
staining cells and less Nissl staining cells found
perihematoma at 1, 3 and 7 days after ICH in AQP4/
mice than AQP4+/+ mice (p< 0.05). RhG-CSF injected
intraperitoneally decreased TUNEL staining cells as well
as increased Nissl staining cells in both types of mice at
all time points after ICH (p< 0.05), but the above
diﬀerence between them still existed (p< 0.05)
Fig. 3. Expression of AQP4, VEGF and VEGFRs. (A, B) Western blot analysis showed rhG-CSF up-regulated AQP4 protein expression at normal
striatum (n= 6, ⁄p< 0.05 vs. control) and surrounding the hematoma in AQP4+/+ mice at 1, 3 and 7 days after ﬁrst injection (n= 6, ⁄p< 0.05 vs.
sham operation, #p< 0.05 vs. ICH). Intracerebroventricular injection of SU5416 had no eﬀect on AQP4 expression changed by rhG-CSF after ICH.
(C, D) Western blot analysis showed rhG-CSF up-regulated Flk-1 expression at normal striatum (n= 6, ⁄p< 0.05 vs. control) as well as
surrounding the hematoma at 1, 3 and 7 days after ﬁrst intraperitoneal injection (n= 6, ⁄p< 0.05 vs. sham operation, #p< 0.05 vs. ICH). While no
such eﬀects on Flt-1 were demonstrated. (E) ELISA showed changes of VEGF protein by rhG-CSF were similar to AQP4 protein both at normal
striatum and surrounding the hematoma (n= 6, ⁄p< 0.05 vs. control, ⁄⁄p< 0.05 vs. sham operation, #p< 0.05 vs. ICH).
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attenuated after injection of SU5416 (p< 0.05) (Fig. 5E,
F). Similarly, a two-way ANOVA with replication showed
F values were 5.04, 5.04, 5.27 and 6.91, 5.39, 5.29 with
the corresponding p values of 0.036, 0.036, 0.033 and
0.016, 0.031, 0.032, suggesting interactions between
G-CSF administration and presence of AQP4 gene existed.Expression of phosphorylation of MAPKs, STAT3 and
Akt by G-CSF in cultured astrocytes
Western blot including semi-quantitative analysis showed
that in cultured astrocytes, p-ERK and p-STAT3 were
up-regulated at 12 h after rhG-CSF administration and
peaked at 48 h (p< 0.05). While no up-regulation of
p-p38, p-JNK or p-Akt was observed within 72 h after
Fig. 4. Eﬀects of G-CSF on ICH in AQP4+/+ and AQP4/ mice. RhG-CSF injected intraperitoneally signiﬁcantly reduced perihematomal brain
water content, brain speciﬁc gravity, EB extravasation amount, neurological scores and numbers of TUNEL staining cells as well as increased Nissl
staining cells at 1, 3 and 7 days after ICH in both types of mice (n= 6, ⁄p< 0.05 vs. sham operation and p< 0.05 vs. ICH). All of the above-
mentioned injuries were more severe in AQP4/ mice comparing with AQP4+/+ mice whether in group of ICH or ICH plus G-CSF (n= 6,
#p< 0.05). Two-way ANOVA with replication showed F (p) values were 5.21 (0.033), 4.86 (0.039), 6.77 (0.017) (A); 4.60 (0.044), 4.83 (0.039) and
5.29 (0.032) (B); 6.13 (0.022), 5.61 (0.040) and 6.33 (0.020) (C); 5.21 (0.033), 5.98 (0.024), 4.62 (0.044) (D); 5.04 (0.036), 5.04 (0.036), 5.27 (0.033)
(E); 6.91 (0.016), 5.39 (0.031), 5.29 (0.032) (F), suggesting interactions between G-CSF administration and presence of AQP4 gene existed in all
sections. (A) Brain water content. (B) Brain speciﬁc gravity. (C) EB extravasation amount. (D) Neurological scores. (E) TUNEL-positive cells. (F)
Nissl staining cells.
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and AQP4 proteins was increased by rhG-CSF after 12 h
and peaked at 48 h (p< 0.05), in accord with the
changing trend of p-ERK and p-STAT3 (Fig. 8).Expression of AQP4 and VEGF proteins in each
group of cultured astrocytes
Since AQP4, VEGF, p-ERK and p-STAT3 all peaked at
48 h after rhG-CSF administration, we selected this time
point in this section. ELISA showed that up-regulation of
VEGF by rhG-CSF was suppressed by AG490, a
STAT3 inhibitor, not other inhibitors (p< 0.05)
(Fig. 9A). To present the morphology of AQP4 protein in
cultured astrocytes, we highlighted the nuclei by DAPI
staining. Diﬀerent from the polarized distribution in brain
tissues, expression of AQP4 protein was found
homogeneously distributed in the cytoplasm of cultured
astrocytes. Both Western blot and immunoﬂuorescence
revealed that rhG-CSF up-regulated AQP4 protein
expression in astrocytes (p< 0.05), which was inhibited
only by U0126, an ERK inhibitor (p< 0.05) (Fig. 9B–I).DISCUSSION
Limited researches on G-CSF and ICH reveal positive
results, including reduction of perihematomal brainedema, BBB permeability and numbers of apoptotic
cells with improvement of neurological functions (Park
et al., 2005; Zhang et al., 2009). However, the eﬀects
were only focused on isolated time points and lack of
dynamic and continuous observation. To date, the
involved mechanisms remain unknown. In the present
study, we put emphasis on perihematomal tissue
injuries, the key pathologic damage in ICH and we
chose the three time points: 1, 3 and 7 days after ICH,
which are just in phases of injuries starting, aggravation
and elimination respectively. We found that G-CSF
signiﬁcantly alleviated perihematomal brain edema, BBB
permeability, apoptosis and death of neural cells with
improvement of neurological functions at all chosen time
points. These ﬁndings are consistent with previous
studies, suggesting protective eﬀects of G-CSF on
perihematomal tissue injuries. We further investigated
the involved mechanisms: whether G-CSF elicited its
protective eﬀects by regulating the expression of VEGF
and AQP4.
G-CSF is closely related with VEGF. It was reported
that administration of G-CSF can increase VEGF and its
receptors in normal rat brain and cultured cells (Ohki
et al., 2005; Jung et al., 2006). We observed the similar
results in normal mice and ﬁrst found intraperitoneal
injection of G-CSF was able to up-regulate
perihematomal VEGF protein expression. Furthermore,
Fig. 5. Inﬂuence of SU5416 to G-CSF’s eﬀects on ICH. Except EB extravasation amount, G-CSF’s eﬀects of reducing perihematomal brain water
content, brain speciﬁc gravity, neurological scores, numbers of TUNEL staining cells and increasing Nissl staining cells at 1, 3 and 7 days after ICH
were attenuated by intracerebroventricular injection of SU5416. But these protective eﬀects still existed in spite of SU5416 injection (n= 6,
⁄p< 0.05 vs. ICH and ICH plus G-CSF, #p< 0.05 vs. ICH). (A) Brain water content. (B) Brain speciﬁc gravity. (C) EB extravasation amount. (D)
Neurological scores. (E) TUNEL-positive cells. (F) Nissl staining cells.
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not Flt-1 both in normal striatum and surrounding the
hematoma at any chosen time point. So we speculated
that VEGF’s protective eﬀects mainly relied on Flk-1 and
Flk-1 speciﬁc inhibitor SU5416 was selected to examine
the hypothesis. In the current study, intracere-
broventricular injection of SU5416 attenuated the
eﬀects of G-CSF on alleviating neurological deﬁcits,
perihematomal brain edema, neuronal death and
apoptosis, only the G-CSF’s eﬀects on BBB perme-
ability remaining unchanged. This indicates VEGF may
mediate G-CSF’s protective eﬀects on perihematomal
tissue injuries.
VEGF is an important neuroprotective factor. It has
been proven that VEGF can reduce neuronal death and
apoptosis in various CNS diseases, including cerebral
ischemia and ICH (Lee et al., 2007; Feng et al., 2010).
We got similar results by TUNEL and Nissl staining and
positive cell counting. The mechanisms include down-
regulation of caspase-3, pro-apoptotic and neurotoxic
proteins such as Bax and Ab1–42, as well as
up-regulation of anti-apoptotic and neurotrophic proteins
such as Bcl-2, Bcl-XL and pigment epithelial-derived
factor (Lee et al., 2007; Feng et al., 2010; Sanchezet al., 2010). It is still controversial how VEGF acts on
brain edema and BBB permeability. Taking cerebral
ischemic models for example, diﬀerent studies showed
various eﬀects of VEGF that it can reduce, not
aggravate, or worsen it (Harrigan et al., 2003; Kaya
et al., 2005; Bates, 2010). VEGF can increase BBB
permeability and ultrastructures in normal state (Rite
et al., 2007), but may counteract with the damage
eﬀects by protecting endothelial cells in case of
pathological damage (Lee et al., 2010). So VEGF is a
factor known to increase BBB permeability but here
SU5416 blocked some of the beneﬁcial eﬀects of
G-CSF and worsened BBB permeability, suggesting that
the direct BBB eﬀects of VEGF in this model are
outweighed by parenchymal eﬀects which may indirectly
aﬀect the BBB. Our recent work revealed VEGF
reduced brain edema surrounding hematoma but had no
inﬂuence on BBB permeability following ICH (Chu et al.,
2013). This is consistent with the current results.
However, SU5416 attenuated but not counteracted
G-CSF’s protective eﬀects, suggesting there may be
other protective mechanisms involved.
Although both G-CSF and AQP4 play important roles
in brain edema, there has been no direct research
Fig. 6. TUNEL staining of each AQP4+/+ and AQP4/ mice group. TUNEL-positive cells (arrows) are seen as TUNEL and DAPI staining double-
labeled surrounding the hematoma zones (asterisks). The changing trend of TUNEL-positive cells in microscopic images were consistent with cell
counting (Fig. 4E). RhG-CSF had no eﬀect on TUNEL staining in normal mice. There were more apoptotic cells in AQP4/ mice than AQP4+/+
mice in ICH and ICH plus G-CSF groups. RhG-CSF decreased perihematomal TUNEL-positive cells in both AQP4+/+ and AQP4/ mice, which
was not inﬂuenced by SU5416. (A) Groups of control, control plus G-CSF and sham operation at 3 days. (B) Groups of ICH, ICH plus G-CSF and
ICH plus G-CSF plus SU5416 at 1, 3 and 7 days after ICH. Scale bar = 50 lm.
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that intraperitoneal injection of G-CSF signiﬁcantly
up-regulated AQP4 protein expression at normal
striatum as well as surrounding the hematoma. Since
VEGF was also reported to increase AQP4 expression
(Rite et al., 2008) and G-CSF up-regulated VEGF in ourstudy, did the above eﬀects of VEGF have something
to do with up-regulation of AQP4 by increased
endogenous VEGF? Furthermore, we found SU5416
was not able to block the up-regulation of AQP4 by
G-CSF, indicating AQP4 was not increased by
endogenous VEGF and they play independent roles in
Fig. 7. Nissl staining of each AQP4+/+ and AQP4/mice group. The changing trend of Nissl staining cells in microscopic images was the same as
the quantitative analysis in cell counting (Fig. 4F). Injection of rhG-CSF had no eﬀect on Nissl staining in normal mice. At the three time points,
marked neuron loss perihematoma was found in AQP4/ mice when compared to AQP4+/+ mice. Besides, rhG-CSF increased perihematomal
Nissl staining cells in both AQP4+/+ and AQP4/ mice, which was not inﬂuenced by SU5416. (A) Groups of control, control plus G-CSF and sham
operation at 3 days. (B) Groups of ICH, ICH plus G-CSF and ICH plus G-CSF plus SU5416 at 1, 3 and 7 days after ICH. Asterisks represent the
hematoma zones. Scale bar = 50 lm.
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possibility of AQP4 being involved in exogenous
G-CSF’s eﬀects on ICH. We demonstrated that AQP4/
mice had more severe perihematomal tissue injuries
than AQP4+/+ mice after ICH, which was similar to our
previous study (Tang et al., 2010). Meanwhile, G-CSF
induced protective eﬀects in both AQP4+/+ and AQP4/
mice after ICH, but injuries in AQP4/ mice were stillmore severe than AQP4+/+ mice. To investigate
whether these eﬀects of G-CSF had something to do with
AQP4, we studied the interactions between G-CSF
injection and presence of AQP4 gene by a two-way
ANOVA with replication. We found interactions between
G-CSF administration and presence of AQP4 gene,
indicating that AQP4 is also involved in G-CSF’s such
eﬀects.
Fig. 8. Expression of phosphorylation of MAPKs, STAT3, Akt, AQP4 and VEGF inﬂuenced by rhG-CSF in cultured astrocytes. RhG-CSF up-
regulated p-ERK, p-STAT3, AQP4 and VEGF proteins at 12 h after administration and expression of these proteins reached maximum at 48 h
(n= 6, ⁄p< 0.05 vs. 0 h; #p< 0.05 vs. 0, 12, 24 and 72 h). While no up-regulation of p-p38, p-JNK or p-Akt was observed within 72 h after rhG-
CSF administration. (A) Western blot image. (B) Semi-quantiﬁcation analysis. (C) ELISA for VEGF protein expression.
Fig. 9. Eﬀects of signal pathway inhibitors on VEGF and AQP4 expression. (A) ELISA showed that VEGF protein was up-regulated by rhG-CSF,
which was suppressed by STAT3 inhibitor AG490 (n= 6, ⁄p< 0.05 vs. control, #p< 0.05 vs. G-CSF). (B–I) Both Western blot and
immunoﬂuorescence revealed that rhG-CSF increased AQP4 protein expression in astrocytes, which was inhibited by U0126, an ERK inhibitor
(n= 6, ⁄p< 0.05 vs. control, #p< 0.05 vs. G-CSF). (B) Western blot analysis. (C) Group of control. (D) Group of G-CSF. (E) Group of G-CSF plus
U0126, an ERK inhibitor. (F) Group of G-CSF plus SB239063, a p38-MAPK inhibitor. (G) Group of G-CSF plus SP600125, a JNK inhibitor. (H)
Group of G-CSF plus AG490, a STAT3 inhibitor. (I) Group of G-CSF plus Ly294002, a PI3K inhibitor. Nuclei are highlighted by DAPI staining. Scale
bar = 50 lm.
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resolution of brain edema as well as has more eﬀects
on glial cells. It has been proven that AQP4 is involved
in formation of cytotoxic edema and elimination of
vasogenic edema (Verkman, 2009). Vasogenic edema
caused by BBB disruption starts several hours after ICHand peaks at several days with secondary cellular injury
giving rise to cytotoxic edema. Among the multiple types
of edema presented after ICH, the main form is
probably vasogenic (Xi et al., 2006; Reggio and Loretol,
2010). The time points chosen in our study are just in
phases of vasogenic edema formation, peak, and
H. Chu et al. / Neuroscience 260 (2014) 59–72 71elimination after ICH. Therefore, the brain edema reduced
by G-CSF in the three phases of ICH partially results from
AQP4 up-regulation to enhance elimination of vasogenic
edema. Moreover, AQP4 is highly concentrated in
astrocyte foot processes surrounding capillaries, which
is an important target for BBB integrity maintenance.
Previous studies highlighted the importance of AQP4 in
maintaining integrity of BBB in development and adult
individuals (Nico et al., 2001; Zhou et al., 2008). In our
previous study, electron micrographs showed that
expression of AQP4 suppressed the perivascular space
widening and endothelial cell swelling after ICH when
compared with the AQP4/ mice group (Tang et al.,
2010). Therefore, we speculate that increase of AQP4
expression after ICH can maintain BBB integrity by
protecting astrocytes and tight junction. AQP4 was
reported to regulate the level of glutamate, a neurotoxic
factor, to inhibit neuronal death (Li et al., 2006; Zeng
et al., 2007). Meanwhile, reactive oxygen species (ROS)
may be involved in AQP4’s eﬀect of regulating
apoptosis (Esposito et al., 2008). In addition, our recent
study showed AQP4 was involved in VEGF’s protective
eﬀects on ICH (Chu et al., 2013). Put together with the
above ﬁndings and results of our current study, eﬀects
of G-CSF to alleviate perihematomal tissue injuries are
AQP4 dependent.
It has been proven that biological eﬀects of G-CSF
mainly rely on activation of JAK/STAT pathway after
combination with its receptor (Harada et al., 2005).
Besides, G-CSF can also activate MAPK and PI3K/Akt
pathways (Huang et al., 2007; Carvalho et al., 2011). In
our work, we demonstrated that G-CSF increased
p-ERK and p-STAT3 in cultured astrocytes, implying
G-CSF activated ERK and JAK/STAT3 pathways.
Meanwhile, the changing trend of VEGF by G-CSF was
consistent with p-STAT3 and STAT3 inhibitor AG490
prevented VEGF up-regulation. Previous researches
indicated VEGF was up-regulated by activation of JAK/
STAT3 pathway in CNS under physiological and
pathological states (Loeﬄer et al., 2005; Jung et al.,
2006). So it is possible that G-CSF up-regulates VEGF
expression due to JAK/STAT3 pathway activation.
Similarly, AQP4 protein and p-ERK were increased and
peaked at the same time course by G-CSF
administration, and this phenomenon was suppressed
by an ERK inhibitor, U0126. Besides, the inhibitors of
ERK and p38-MAPK were reported to suppress AQP4
up-regulation induced by manganese-treated or oxygen-
glucose deprivation and recovery (Rao et al., 2010; Qi
et al., 2011). Therefore, it is not hard to speculate that
G-CSF increases AQP4 expression via ERK pathway.CONCLUSION
We demonstrate that G-CSF has protective eﬀects on
perihematomal tissue injuries following ICH. Besides,
we also ﬁnd that the eﬀects of G-CSF to reduce
perihematomal brain edema, neuronal death and
apoptosis, and neurological deﬁcits are closely
related with VEGF and AQP4 up-regulation, while
G-CSF’s eﬀect on alleviating BBB leakage is only AQP4dependent. In addition, our study reveals that VEGF
and AQP4 up-regulation by G-CSF maybe results from
the activation of STAT3 and ERK pathways
respectively. The current study provides triple targets to
treatment of perihematomal tissue injuries following ICH,
which can present new insights to drugs development.
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